Scott Tarriff - Eagle Pharmaceuticals CEO
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
CEO
Mr. Scott L. Tarriff is Chief Executive Officer, Director of Eagle Pharmaceuticals, Inc. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc., a publiclytraded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with BristolMyers Squibb, a publiclytraded biopharmaceutical company, including senior directormarketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publiclytraded biotechnology company, since February 2012 and as a director of Ziopharm Oncology, Inc., a publiclytraded biotechnology company, since September 2015 and previously served on the board of directors of Clinical Data, Inc., a publiclytraded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc since 2017.
| Age | 64 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Scott Tarriff Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Tarriff against Eagle Pharmaceuticals pink sheet is an integral part of due diligence when investing in Eagle Pharmaceuticals. Scott Tarriff insider activity provides valuable insight into whether Eagle Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Eagle Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eagle Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Tarriff over six months ago Payment of 2119 shares by Scott Tarriff of Eagle Pharmaceuticals subject to Rule 16b-3 | ||
Scott Tarriff over six months ago Disposition of 3154 shares by Scott Tarriff of Eagle Pharmaceuticals at 6.44 subject to Rule 16b-3 | ||
Scott Tarriff over six months ago Sale by Scott Tarriff of 7802 shares of Eagle Pharmaceuticals | ||
Scott Tarriff over a year ago Sale by Scott Tarriff of 10925 shares of Eagle Pharmaceuticals |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Eagle Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eagle Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eagle Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eagle to invest in growth at high rates of return. When we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | CEO Age | ||
| Nikhil Lalwani | ANI Pharmaceuticals | 46 | |
| Vikram Karnani | Collegium Pharmaceutical | 49 | |
| David Moatazedi | Evolus Inc | 46 | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Gaozhong Zhu, Senior Development | ||
| Reiner Nowak, Exec | ||
| Ryan Debski, General VP | ||
| John Kimmet, Ex Care | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| Valentin MD, Senior Development | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |